^
Association details:
| Biomarker: | HER-2 positive + MYC amplification |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1561P - APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)
Published date:
10/16/2023
Excerpt:
Patients were treated with S-1 80 mg/m2/day or Capecitabine 2000 mg/m2/day on days 1-14 with oxaliplatin 130 mg/m2, N-mab 360mg, and T-mab 8mg/kg for initial treatment, and subsequently with 6 mg/kg on day 1, repeated every 3 weeks....Patients with MYC amp. showed significantly shorter PFS (median 4.2 vs 18.0 months, HR 3.48, 95%CI 1.09-11.12, p = 0.024) and OS (median 13.9 months vs not reached, HR 3.97, 95%CI 0.95-16.54, p = 0.042), respectively.
Secondary therapy:
oxaliplatin + gimeracil/oteracil/tegafur; capecitabine + oxaliplatin
